FDA Approves Eohilia (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis

OSAKA, Japan and CAMBRIDGE, Massachusetts, February 12, 2024– Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved Eohilia (budesonide oral suspension), the first and only FDA-approved oral...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news